Presentation to highlight statistically significant Phase 3 results of Tonmya™ (TNX-102 SL) for the management of fibromyalgia
New Drug Application (NDA) submission to the FDA on track for the second half of 2024
CHATHAM, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced a poster presentation at the Annual European Congress of Rheumatology (EULAR) 2024, being held June 12-15, 2024 at the Messe Wien Congress Center in Vienna, Austria. Details on the presentation can be found below.
A copy of the Company's poster presentations will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional meeting information can be found on the EULAR website here.
Poster Presentation Details
Presenter: | Iredell Iglehart, M.D. |
Title: | Targeting Non-Restorative Sleep in Fibromyalgia with Bedtime TNX-102 SL (Sublingual Cyclobenzaprine HCl) Significantly Improves Pain in RESILIENT, a Confirmatory Phase 3 Randomized Clinical Trial |
Room: | Poster Tour 2 |
Abstract: | POS0324 |
Date/Time: | Friday, June 14, 2024, 12:36 p.m. CEST |
Tonix Pharmaceuticals Holding Corp.*
Tonix is a fully-integrated biopharmaceutical ...